Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Mar;73(3):309-315.
doi: 10.1053/j.ajkd.2018.10.006. Epub 2018 Dec 19.

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

Finnian R Mc Causland  1 , Brian Claggett  2 , Emmanuel A Burdmann  3 , Glenn M Chertow  4 , Mark E Cooper  5 , Kai-Uwe Eckardt  6 , Peter Ivanovich  7 , Andrew S Levey  8 , Eldrin F Lewis  2 , Janet B McGill  9 , John J V McMurray  10 , Patrick Parfrey  11 , Hans-Henrik Parving  12 , Giuseppe Remuzzi  13 , Ajay K Singh  14 , Scott D Solomon  2 , Robert D Toto  15 , Marc A Pfeffer  2
Affiliations
Randomized Controlled Trial

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

Finnian R Mc Causland et al. Am J Kidney Dis. 2019 Mar.

Abstract

Rationale & objective: Evidence from clinical trials to guide patient preparation for maintenance dialysis therapy is limited. Although anemia is associated with mortality and cardiovascular (CV) disease in individuals initiating maintenance dialysis therapy, it is not known if treatment of anemia before dialysis therapy initiation with erythropoiesis-stimulating agents alters outcomes.

Study design: Post hoc analysis of a randomized controlled trial.

Setting & participants: Participants with type 2 diabetes and chronic kidney disease who progressed to dialysis therapy (n=590) in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Exposure: Randomized treatment assignment (darbepoetin vs placebo).

Outcomes: All-cause mortality, CV mortality, nonfatal myocardial infarction, heart failure, and stroke within the first 180 days of dialysis therapy initiation.

Analytical approach: Proportional hazards regression.

Results: Overall, 590 of 4,038 (14.6%) participants initiated dialysis therapy during the trial (n=298 and 292 in the darbepoetin and placebo groups, respectively). Corresponding hemoglobin levels were 11.3±1.6 and 9.5±1.5g/dL (P<0.001). Death from any cause occurred in 31 (10.4%) participants assigned to darbepoetin and 28 (9.6%) assigned to placebo (HR, 1.16; 95% CI, 0.69-1.93), while death from CV causes occurred in 15 (5.0%) and 13 (4.5%) participants, respectively (HR, 1.21; 95% CI, 0.58-1.93). There were no differences in risk for nonfatal myocardial infarction or heart failure. Stroke occurred in 8 (2.8%) participants assigned to darbepoetin and 1 (0.3%) assigned to placebo (HR, 8.6; 95% CI, 1.1-68.7).

Limitations: Post hoc analyses of a subgroup of study participants.

Conclusions: Despite initiating dialysis therapy with a higher hemoglobin level, prior treatment with darbepoetin was not associated with a reduction in mortality, myocardial infarction, or heart failure in the first 180 days, but a higher frequency of stroke was observed. In the absence of more definitive data, this may inform decisions regarding the use of erythropoiesis-stimulating agents to treat mild to moderate anemia in patients with type 2 diabetes and chronic kidney disease nearing dialysis therapy initiation.

Keywords: Anemia; cardiovascular disease; chronic kidney disease (CKD); darbepoetin; death; dialysis; dialysis initiation; erythropoiesis stimulating agent (ESA); hemoglobin (Hb); incident dialysis; stroke; transition to dialysis; type 2 diabetes mellitus (T2DM).

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow diagram of participant selection
Figure 2.
Figure 2.
Kaplan-Meier plot examining effect of randomized treatment assignment on all-cause mortality from time of maintenance dialysis initiation to 6 months
Figure 3.
Figure 3.
Kaplan-Meier plot examining effect of randomized treatment assignment on stroke from time of maintenance dialysis initiation to 6 months
See this image and copyright information in PMC

Comment in

References

    1. USRDS 2016 Annual Data Report.
    1. Robinson BM, Zhang J, Morgenstern H, et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. Kidney International. 2014;85(1):158–165. doi:10.1038/ki.2013.252. - DOI - PMC - PubMed
    1. Eckardt K-U, Gillespie IA, Kronenberg F, et al. High cardiovascular event rates occur within the first weeks of starting hemodialysis. Kidney International. 2015;88(5):1117–1125. doi:10.1038/ki.2015.117. - DOI - PMC - PubMed
    1. El-Achkar TM, Ohmit SE, McCullough PA, et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005;67(4):1483–1488. doi:10.1111/j.1523-1755.2005.00226.x. - DOI - PubMed
    1. Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care. 2003;26(4):1164–1169. - PubMed

Publication types